A monoclonal antibody targeting vascular endothelial growth factor, was approved as antiangiogenic therapy. Antiangiogenesis therapy is one of two types of drugs in a new class of medicines that restores health by controlling blood vessel growth.The other medication is called pro-angiogenic therapy. Antiangiogenic therapy inhibits the growth of new blood vessels. Because new blood vessel growth plays a critical role in many disease conditions, including disorders that cause blindness, arthritis, and cancer.
Related journals of Antiangiogenic Therapies
Journal of Oncology Translational Research, Nuclear Medicine & Radiation Therapy, Chemotherapy: Open Access, Cancer Medicine & Anti Cancer Drugs, Cancer Diagnosis, Cancer Gene Therapy, Cancer Gene Therapy Week, Gene Therapy, Integrative Cancer Therapies, Cancer Therapy, Current Cancer Therapy Reviews.